Taiwan · Delayed Price · Currency is TWD Bionime Statistics
Total Valuation
Bionime has a market cap or net worth of TWD 4.41 billion. The enterprise value is 6.27 billion.
| Market Cap | 4.41B |
| Enterprise Value | 6.27B |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bionime has 77.29 million shares outstanding. The number of shares has increased by 6.58% in one year.
| Current Share Class | 77.29M |
| Shares Outstanding | 77.29M |
| Shares Change (YoY) | +6.58% |
| Shares Change (QoQ) | +5.53% |
| Owned by Insiders (%) | 7.48% |
| Owned by Institutions (%) | 0.62% |
| Float | 48.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.57 |
| PB Ratio | 2.09 |
| P/TBV Ratio | 3.74 |
| P/FCF Ratio | 185.64 |
| P/OCF Ratio | 34.99 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 264.11 |
Financial Position
The company has a current ratio of 0.77, with a Debt / Equity ratio of 1.06.
| Current Ratio | 0.77 |
| Quick Ratio | 0.45 |
| Debt / Equity | 1.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | 94.17 |
| Interest Coverage | -4.83 |
Financial Efficiency
Return on equity (ROE) is -14.16% and return on invested capital (ROIC) is -7.41%.
| Return on Equity (ROE) | -14.16% |
| Return on Assets (ROA) | -3.39% |
| Return on Invested Capital (ROIC) | -7.41% |
| Return on Capital Employed (ROCE) | -8.51% |
| Weighted Average Cost of Capital (WACC) | 3.11% |
| Revenue Per Employee | 3.43M |
| Profits Per Employee | -572,640 |
| Employee Count | 500 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 2.21 |
Taxes
| Income Tax | -94.33M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.17% in the last 52 weeks. The beta is -0.13, so Bionime's price volatility has been lower than the market average.
| Beta (5Y) | -0.13 |
| 52-Week Price Change | -15.17% |
| 50-Day Moving Average | 56.56 |
| 200-Day Moving Average | 58.73 |
| Relative Strength Index (RSI) | 52.53 |
| Average Volume (20 Days) | 68,044 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bionime had revenue of TWD 1.72 billion and -286.32 million in losses. Loss per share was -4.00.
| Revenue | 1.72B |
| Gross Profit | 576.21M |
| Operating Income | -306.95M |
| Pretax Income | -377.78M |
| Net Income | -286.32M |
| EBITDA | -154.34M |
| EBIT | -306.95M |
| Loss Per Share | -4.00 |
Balance Sheet
The company has 383.71 million in cash and 2.23 billion in debt, with a net cash position of -1.85 billion or -23.95 per share.
| Cash & Cash Equivalents | 383.71M |
| Total Debt | 2.23B |
| Net Cash | -1.85B |
| Net Cash Per Share | -23.95 |
| Equity (Book Value) | 2.11B |
| Book Value Per Share | 27.13 |
| Working Capital | -464.09M |
Cash Flow
In the last 12 months, operating cash flow was 125.91 million and capital expenditures -102.18 million, giving a free cash flow of 23.73 million.
| Operating Cash Flow | 125.91M |
| Capital Expenditures | -102.18M |
| Depreciation & Amortization | 152.62M |
| Net Borrowing | -433.27M |
| Free Cash Flow | 23.73M |
| FCF Per Share | 0.31 |
Margins
Gross margin is 33.55%, with operating and profit margins of -17.87% and -16.67%.
| Gross Margin | 33.55% |
| Operating Margin | -17.87% |
| Pretax Margin | -22.00% |
| Profit Margin | -16.67% |
| EBITDA Margin | -8.99% |
| EBIT Margin | -17.87% |
| FCF Margin | 1.38% |
Dividends & Yields
Bionime does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.58% |
| Shareholder Yield | -6.58% |
| Earnings Yield | -6.50% |
| FCF Yield | 0.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 8, 2025. It was a forward split with a ratio of 1.0998680158.
| Last Split Date | Sep 8, 2025 |
| Split Type | Forward |
| Split Ratio | 1.0998680158 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |